Dr. Anirban Das, Receives Esteemed Nomination in Immunotherapy Research
We are excited to share that our new paper on immunotherapy was nominated by the Canadian Cancer Immunotherapy Consortium (CCIC) for an oral presentation at the World Immunotherapy Council (WIC) for Young Investigators at SITC 2023. This nomination is in recognition of scientific excellence in the field of cancer immunotherapy.
Congratulations to Dr. Anirban Das for this prestigious nomination
Exciting New Advancements in RRD Glioma Treatment
We are thrilled to share the release of a new research paper, spearheaded by Dr. Anirban Das in collaboration with an international team of IRRDC members.
Dr. Anirban Das
Entitled “Combining Immunotherapies to Improve Outcomes in Replication Repair Deficient (RRD) High-Grade Gliomas that Don’t Respond to Anti-PD1 Monotherapy,” this paper highlights promising approaches for patients with tumors that don’t initially respond well to the standard treatment. Specifically, it reveals how combining immunotherapies after anti-PD1 monotherapy failure can significantly extend survival, particularly for those with a high mutation burden. This research unveils encouraging and delayed responses and emphasizes the importance of personalized treatment approaches.
Talks Now Available from our 3rd Education Seminar
We are happy to announce that the talks from our third education series are now available to watch on our website and on YouTube.
This seminar featured two speakers, as well as a brief Q&A period following each presentation. The first talk was by Ayse Ercan who presented the results of her large study on phenotype-genotype relationships within our registry. The second talk was given by Dr. Liana Nobre who described a novel diagnostic tools currently in the process of clinical translation for monitoring and treating CMMRD.
The event closed with a 25-minute panel-discussion session addressing frequently asked questions we receive from patients.
The IRRDC is pleased to share our second newsletter, which highlights recent work that has advanced our understanding of immune-based therapies for patients with CMMRD. We welcome you to contact us regarding any questions, comments, or feedback. Enjoy!
February 1, 2022
Congratulations to Dr. Das and the team! Our newest research recently published in Nature Medicine finds that immune-based therapy may help treat certain childhood cancers that are resistant to more common cancer treatments such as chemotherapy and radiation therapy. You can read more about this work here.
Inaugural Newsletter and Second Education Night
October 27th, 2021
We are very excited to announce that we have published the first issue of our inaugural newsletter which contains recent research highlights and articles written by members of our team and global family. We encourage you to share this newsletter with those you feel may be interested in our latest work.
In addition, we would like to announce our second educational seminar which will be held virtually on November 30th from 8-9am EST. Details can be found on our Eventbrite Page . If you are interested in attending this event, please register on Eventbrite. A link to the webinar will be provided the week before the event. For those who cannot attend live, the talks will be recorded and disseminated to those registered following the event.
Congratulations to Yash Krishnan!
October 21st, 2021
We would like to extend a huge congratulations to the incredible Yash Krishnan for his award nomination for “Federal or State Advocacy by a Teenager” through the EveryLife Foundation for Rare Diseases. This award honours teen advocates that have advocated for novel state or federal legislation
Yash and his family play an enormous role in our group as patient and parent advocates. They are dedicated to raising awareness and funding for CMMRD and other rare diseases by engaging with the FDA and international politicians. We are so grateful to have them as part of this team.
Education Night Talks
July 15, 2021
The talks from our very first education night (held on April 1st, 2021) are now available
Please follow this link to our Education Night page to see our inaugural talks, where Dr. Vanessa Bianchi discusses how following a surveillance protocol has greatly improved survival for individuals with CMMRD, and Dr. Victoria Forster discusses how we can use some CMMRD patient samples to generate “mini-organs” which may be used for a personalised medicine approach to patient care in the future.
New Surveillance Publication in JCO
May 5, 2021
Congratulations to Carol Durno, Ayse Bahar Ercan, Vanessa Bianchi, Uri Tabori and many additional collaborators from the RRD consortium for their landmark study on the efficacy of the surveillance protocol, now published in the Journal of Clinical Oncology.
Major findings from this study include:
Surveillance enables early tumour detection
100% of GI and solid tumours, and 75% of brain tumours were identified asymptomatically in patients undergoing surveillance
Four-year survival was 79% for patients who adhered to the full protocol, in contrast to only 15% for patients not under surveillance. Strikingly, four-year survival was still 55% for patients who only had partial surveillance.
Low-grade tumors identified by surveillance have a high likelihood of transforming, emphasizing the need for early detection and resection.
100% of low-grade tumors that were not resected transformed to high-grade within 6 years.
Ultimately, these results emphasise the momentous survival benefit of surveillance in patients with CMMRD.
Congratulations to Melissa Galati and the rest of the IRRDC for their new publication in Cancer Discovery, showing that treatment of patients with RAS/MAPK hypermutant gliomas have durable responses to MEK inhibition.
New diagnostic criteria for CMMRD published by the international working group based on novel tools.
A new paper has been published by Melyssa Aronson and an amazing team of international collaborators. This paper details seven diagnostic criteria for the diagnosis of CMMRD that were developed during our Annual RRD Workshop in 2017. The criteria incorporate germline mismatch repair results, novel tools and clinical characteristics to determine a diagnosis, and provides updated guidelines for health-care providers.
Read their recommendations:
Sign up for our newsletter!
We release a bi-annual newsletter for the International Replication Repair Deficiency Consortium. Fill out the form below or contact us directly to join our mailing list.